1 Major Factor Behind the Healthcare Sector’s Recent Surge
Eli Lilly’s GLP-1 drug became the world’s best-selling drug in Q3. Merck, Johnson & Johnson, AbbVie, and other…
Earlier use of CARVYKTI® demonstrated lasting treatment-free remissions at 2.5 years in patients with relapsed or refractory multiple myeloma
Follow-up data from CARTITUDE-4 show at least 80 percent of as-treated standard-risk patients remained progression and treatment-free following…
Johnson & Johnson Buys Prostate Cancer Treatment-Maker Halda for $3.1 Billion
Johnson & Johnson has had the year 2025 circled, highlighted, bolded and underlined on its calendar for a…
What’s likely to move the market in the next trading session
Stocks @ Night is a daily newsletter delivered after hours, giving you a first look at tomorrow and…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Why big pharma is teaming up with AI giants to speed up drug discovery and make work easier for health care workers
AI chip maker Nvidia’s fresh partnerships with Eli Lilly and Johnson & Johnson point to a broader trend…
Stock market today: Live updates
Traders work on the floor of the New York Stock Exchange (NYSE) on November 07, 2025 in New…
Texas AG Ken Paxton moves to block Tylenol maker dividend amid lawsuit over marketing
Texas Attorney General Ken Paxton has filed a motion to block Kenvue, the maker of Tylenol, from issuing…
Trump, RFK Jr. and Texas lawsuits slam Kenvue
Kenvue, the company that makes Tylenol, is fighting on both the political and scientific fronts. The latest blow…
Tylenol, Kleenex, Band-Aid and more put under one roof in $48.7 billion consumer brands deal
Kimberly-Clark is buying Tylenol maker Kenvue in a cash and stock deal worth about $48.7 billion, creating a…
Nipocalimab significantly decreased Sjögren’s disease (SjD) activity and severity through substantial reduction in Sjögren’s-related autoantibodies
Nipocalimab, a first-in-class FcRn blocker being investigated for SjD, met its primary endpoint in the Phase 2 DAHLIAS…
What we know as Johnson & Johnson sued by thousands in UK over talcum powder
Thousands of people are launching a collective legal challenge against healthcare giant Johnson & Johnson (J&J), claiming it…